Johnson & Johnson (NYSE:JNJ) Stock Position Decreased by WealthPLAN Partners LLC

WealthPLAN Partners LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,185 shares of the company's stock after selling 2,955 shares during the quarter. Johnson & Johnson makes up about 0.9% of WealthPLAN Partners LLC's investment portfolio, making the stock its 28th biggest position. WealthPLAN Partners LLC's holdings in Johnson & Johnson were worth $6,101,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. AMF Tjanstepension AB increased its stake in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after acquiring an additional 52,997 shares during the last quarter. Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson during the third quarter worth approximately $209,000. Wealth Group Ltd. acquired a new stake in shares of Johnson & Johnson in the third quarter worth $213,000. Swedbank AB raised its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after acquiring an additional 111,570 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI lifted its holdings in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company's stock valued at $15,798,000 after acquiring an additional 1,768 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ traded up $2.67 during trading hours on Friday, hitting $162.35. The company's stock had a trading volume of 12,540,171 shares, compared to its average volume of 9,073,381. The company has a 50-day simple moving average of $148.93 and a 200 day simple moving average of $155.90. The firm has a market capitalization of $390.87 billion, a PE ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter in the previous year, the company posted $2.29 EPS. The business's revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Raymond James lowered their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.